Nano Vivere (ISIN: CN0024013913), a late stage clinical company, pioneering nanomedicine whose technology is based on proprietary technologies and patents, today announced that researchers have developed nanometer-sized drones that deliver drugs to heal and stabilize fat deposits in arteries that could prevent heart attacks caused by atherosclerosis.

Most people don’t hear the word “Atherosclerosis” until it’s too late. Atherosclerosis of the coronary arteries, which is the build-up of fats, cholesterol, and other substances in and on the artery walls, is the number one killer of women and men in the United States, according to several studies.

Researchers have created nanomedicines – 1000 times smaller than the tip of a single strand of human hair – from polymeric building blocks that carry an anti-inflammatory drug.

In the study, which was conducted on mice, the nano drones reach the plaque within hours and slowly release the drug. The nanoparticles use biodegradable polymers engineered to carry the healing, stabilizing anti-inflammatory peptides. The polymers are designed to break up over time in the body.

Following five weeks of treatment with this method, the study says, damage to the arteries was significantly repaired and plaque was stabilized.
Current treatments have reduced the number of atherosclerosis-related deaths, but it remains a dangerous health problem. However, “this is the first example of a targeted nanoparticle technology that reduces atherosclerosis in an animal model,” says a senior, MD, associate professor and director of the study.

The study admits trials on humans are a long way off and require more potent drugs, but the researchers also expect that better delivery methods of the medicine will be discovered.

“Many researchers are trying to develop drugs that prevent heart attacks by tamping down inflammation, but that approach has some downsides,” says the researcher. “One is that atherosclerosis is a chronic disease, so drugs are taken for years, even decades. An anti-inflammatory drug that is distributed throughout the entire body will also impair the immune system’s ability to fight infection.”

About Nano Vivere (ISIN: CN0024013913)
Nano Vivere is a late stage clinical company, pioneering nanomedicine that is following its unique path: a new way to treat patients thanks to nanophysics delivered at the cell’s nucleus. The company’s technology is based on proprietary technologies and patents and it operates worldwide from the headquarters based in Guangzhou. Nano Vivere is led by a highly trained and distinguished team of experts who have demonstrated success in the combined fields medicine, biologics, neuroscience, and nanotechnology along with the specialized business development track record requisite for the launch of cutting-edge medical technologies.

http://nanovivere.com/cn/home